<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220961</url>
  </required_header>
  <id_info>
    <org_study_id>02-062A</org_study_id>
    <nct_id>NCT00220961</nct_id>
  </id_info>
  <brief_title>Actos Now for Prevention of Diabetes (ACT NOW)</brief_title>
  <official_title>Actos Now for Prevention of Diabetes (ACT NOW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether pioglitazone versus placebo can reduce the
      conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGT is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, the
      hyperglycemia-related complications of this devastating disease can be prevented. Subjects
      with IGT will be identified with an oral glucose tolerance test (OGTT). Eligible subjects
      also will have a measurement of first phase insulin secretion and insulin sensitivity using
      the frequently sampled intravenous glucose tolerance test (FSIVGTT) and carotid intimal media
      thickness using carotid ultrasound. Following these measurements subjects will be randomized
      to receive pioglitazone or placebo and they will return every 3 months for determination of
      fasting plasma glucose (FPG) concentration and interim medical history. Recruitment will take
      place over 15 months. From the time that the recruitment period ends, subjects will be
      followed for a total of 24 months on pioglitazone or placebo. The OGTT will be repeated at
      15,27, and 39 months, or if the FPG is â‰¥ 126 mg/dl on the 3-month follow up visits. If the
      diagnosis of diabetes is established before month 39 or at month 39, the FSIVGTT and carotid
      ultrasound will be repeated. At 39 months, subjects will be washed out of pioglitazone or
      placebo and the OGTT, FSIVGTT, and carotid ultrasound will be repeated at month 45.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Type 2 Diabetes</measure>
    <time_frame>2.4 years</time_frame>
    <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Fasting Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atherosclerosis</measure>
    <time_frame>Baseline versus 2.4 years</time_frame>
    <description>carotid intima thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet similar to pioglitazone tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone tablet similar to placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone tablets - 45 mg/day</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets similar to pioglitazone tablets - 1 tablet/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  All ethnic groups

          -  18 years of age and older

          -  Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and
             2 hr glucose of 140-199 mg/dl)

          -  At least one of the following:

               -  One or more components of the insulin resistance syndrome (HDL &lt; 40 mg/dl in
                  females and &lt;35 mg/dl in males, fasting triglycerides &gt; 150 mg/dl, blood pressure
                  &gt; 135/85 mmHg, BMI &gt; 24 kg/m2, waist circumference &gt; 102 cm in men and &gt; 88 cm in
                  women)

               -  One or more first degree relatives with type 2 diabetes

               -  History of gestational diabetes

               -  Polycystic ovarian disease

               -  Minority ethnic background (Mexican American, African American, Asian and Pacific
                  Islanders, Native American)

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Previously treated with thiazolidinediones (ever) or metformin (within one year)

          -  Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor
             for more than a week within last year or within the 3 months prior to randomization

          -  Previously treated with insulin (other than during pregnancy) for more than one week
             within the last year or within the 3 months prior to randomization

          -  Cardiovascular disease

          -  Hospitalization for treatment of heart disease or stroke in past 6 months

          -  New York Heart Association Functional Class &gt; 2

          -  Left bundle branch block or third degree AV block

          -  Aortic stenosis

          -  SBP &gt; 180 mmHg or DBP &gt; 105 mmHg

          -  Renal disease

          -  Anemia

          -  Hepatitis

          -  GI diseases (pancreatitis, inflammatory bowel disease)

          -  Recent or significant abdominal surgery

          -  Advanced pulmonary disease

          -  Chronic infections

          -  Weight loss &gt; 10% in past 6 months

          -  Pregnancy and childbearing

          -  Major psychiatric disorders

          -  Excessive alcohol intake

          -  Thiazide use &gt; 25 mg per day

          -  Non-selective beta blockers

          -  Niacin

          -  Systemic glucocorticoids

          -  Weight loss or weight gain medication

          -  Thyroid disease-suboptimally treated

          -  Active endocrine diseases (Cushing's, acromegaly)

          -  Plasma triglycerides over 400 mg/dl (despite treatment)

          -  History bladder cancer

          -  Hematuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A. DeFronzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carl T. Hayden VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC-Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego-San Diego VA Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Health Science Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.org/</url>
    <description>American Diabetes Association</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>June 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2016</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Chief of Diabetes</investigator_title>
  </responsible_party>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Prevention</keyword>
  <keyword>Pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets - 1 tablet/day</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets - 45mg/day tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="0.5"/>
                    <measurement group_id="B2" value="52.3" spread="0.5"/>
                    <measurement group_id="B3" value="52.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevention of Type 2 Diabetes</title>
        <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
        <time_frame>2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Prevention of Type 2 Diabetes</title>
          <description>Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</title>
        <description>Fasting Plasma Glucose</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose of 2.4 Years</title>
          <description>Fasting Plasma Glucose</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.09"/>
                    <measurement group_id="O2" value="-10.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</title>
        <description>Insulin secretion</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test</title>
          <description>Insulin secretion</description>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="5"/>
                    <measurement group_id="O2" value="25" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</title>
        <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)</title>
          <description>Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.</description>
          <units>matsuda index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="3.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atherosclerosis</title>
        <description>carotid intima thickness</description>
        <time_frame>Baseline versus 2.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atherosclerosis</title>
          <description>carotid intima thickness</description>
          <units>percentage of intima</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                    <measurement group_id="O2" value="3.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet similar to pioglitazone tablet
Placebo: Placebo tablets similar to pioglitazone tablets</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone</title>
          <description>Pioglitazone tablet similar to placebo tablet
Pioglitazone: Pioglitazone tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>One unexplained sudden death occurred in the placebo group, and three deaths occurred in the pioglitazone group (one unexplained sudden death, one death from biliary carcinoma, and one death from a carcinoid tumor).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardio infarction, heart failure, other</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="299"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="144" subjects_affected="144" subjects_at_risk="299"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralph DeFronzo, MD</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

